Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Change in Cash: 2016-2025

Historic Change in Cash for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to -$9.4 million.

  • Organogenesis Holdings' Change in Cash fell 310.45% to -$9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.6 million, marking a year-over-year decrease of 683.64%. This contributed to the annual value of $31.8 million for FY2024, which is 2935.59% up from last year.
  • Per Organogenesis Holdings' latest filing, its Change in Cash stood at -$9.4 million for Q3 2025, which was up 74.56% from -$36.8 million recorded in Q2 2025.
  • Organogenesis Holdings' Change in Cash's 5-year high stood at $41.2 million during Q4 2024, with a 5-year trough of -$36.8 million in Q2 2025.
  • For the 3-year period, Organogenesis Holdings' Change in Cash averaged around -$3.5 million, with its median value being $93,000 (2023).
  • As far as peak fluctuations go, Organogenesis Holdings' Change in Cash soared by 1,116.13% in 2024, and later plummeted by 3,353.67% in 2025.
  • Quarterly analysis of 5 years shows Organogenesis Holdings' Change in Cash stood at $11.8 million in 2021, then crashed by 140.08% to -$4.7 million in 2022, then spiked by 216.53% to $5.5 million in 2023, then skyrocketed by 647.78% to $41.2 million in 2024, then slumped by 310.45% to -$9.4 million in 2025.
  • Its Change in Cash stands at -$9.4 million for Q3 2025, versus -$36.8 million for Q2 2025 and -$25.6 million for Q1 2025.